Clover Biopharmaceuticals

Clover Biopharmaceuticals, founded in 2007, is a global, clinical-stage biotechnology firm specializing in the discovery, development, and commercialization of transformative biologic therapies. The company maintains a strategic focus on addressing complex medical needs within the oncology and autoimmune disease sectors. By leveraging a proprietary technology platform, Clover Biopharmaceuticals develops innovative vaccine candidates and therapeutic solutions designed to improve public health outcomes globally. The firm’s commitment to scientific rigor positions it as a key player in the evolving biopharmaceutical landscape, focusing on high-impact disease areas.

The organization currently operates with a workforce of 500-1,000 employees, supporting its mission-driven approach to biopharmaceutical development. With a robust operational footprint, the company integrates research, clinical development, and commercialization efforts to advance its diverse pipeline. Meet Clover Biopharmaceuticals's team to learn about the leadership and technical expertise driving these clinical-stage initiatives. The firm continues to expand its influence in the biopharma landscape through rigorous scientific research, clinical trials, and strategic partnerships that enhance its operational capabilities across international markets.

Financially, Clover Biopharmaceuticals demonstrates significant market activity, reporting annual revenue of $172.0M. The company has successfully secured multiple funding rounds, including a notable $230.0M Series C investment, to support its ongoing research and development programs. As it competes with industry peers like Novavax and BioCryst, the firm remains committed to scaling its therapeutic franchises. Explore financial highlights for detailed metrics regarding the company's capital structure, funding history, and growth trajectory.